Auph short interest.

Initially, Lupkynis seemed to be a promising treatment for LN, but its adoption has fallen short of expectations, as shown by Aurinia's failure to meet its 2022 revenue projections ($115-$135 ...AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...Arrow Financial Co. (NASDAQ:AROW – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 153,000 shares, an increase of 13.1% from the February 28th total of 135,300 shares. Based on an average trading volume of 34,700 shares, the […]Web

Sep 17, 2019 · Exhibit 99.1 Aurinia Pharmaceuticals Inc. Interim Condensed Consolidated Statements of Financial Position (Unaudited) As at March 31, 2019 (expressed in thousands of US dollars) March 31, 2019 $ December 31, 2018 $ Assets Current assets Cash and cash equivalents 140,359 117,967 Short term investments (note 4) 3,975 7,889 Accounts receivable and ... Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, profile. ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas Short Interest. 0.

The 5-day price performance for the stock is 13.73%, and 26.09% over 30 days. With these gigs, the year-to-date price performance is 114.82%. Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover.

Jun 29, 2023 · Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ... Overview of financial data and news for Aurinia Pharmaceuticals Inc., Nasdaq:AUPHAUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia …Arrow Financial Co. (NASDAQ:AROW – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 153,000 shares, an increase of 13.1% from the February 28th total of 135,300 shares. Based on an average trading volume of 34,700 shares, the […]WebAUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...

Institutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQ

22 votes, 16 comments. 1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc.

At the end of Q2 2019, Aurinia had cash, cash equivalents and short-term investments of $150.2 million. Net cash used in operating activities was $12.3 million for Q2 2018 compared to $14.0 ...2 Nov 2023 ... The change is primarily related to change in fair value assumptions driven predominantly by rising interest ... Short-term investments. 291,503.HRTX 1.3100 (+20.18%) Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results Business Wire - Thu May 4, 5:00AM CDT. Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short. With the short side of the trade heavily crowded, and a few shares publicly ...Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value.Introduction. This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by frequency of updates, with intraday data at the top (short shares availability, short borrow fee rate), daily data (short volume, fails-to-deliver) in the middle, and the slowest updated data (short interest) at …WebMar 7, 2022 · The actual guidance provided by AUPH in its earnings release on Feb 28, fell way short of that Wall St number: "For fiscal year 2022, the Company is providing net revenue guidance of $115 to $135 ...

The settlement with Sun Pharma appeared to spark some renewed speculation that the company could be a takeover target again. Dealreporter speculated at the time that Aurinia AUPH could be viewed as a takeout candidate with the patent overhang lifted. Aurinia AUPH short interest is 10.7%.Business, Economics, and Finance. GameStop Moderna Pfizer Johnson & Johnson AstraZeneca Walgreens Best Buy Novavax SpaceX Tesla. CryptoAUPH has multiple downside risks that investors need to consider when managing their position. First, Aurinia is still recording losses and reported a net loss of $82.1M for the first three ...Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short) The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...

Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...

Aurinia Pharmaceuticals Stock (NASDAQ: AUPH) stock price, news, charts, stock research, profile. ... Profile News Analyst Ratings Guidance Dividends Earnings Insider Trades Ideas Short Interest. 0.Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year. Passive investing in index funds can generate returns that roughly …High short interest. Together with FinMasters. See AUPH options chain. ... AUPH quarterly revenue growth was 59.10%, higher than the industry and sector average revenue growth (0.75% and 2.15%, respectively). See AUPH revenue growth chart. AUPH profitability is improving. The YoY profit margin change was 3006.43 percentage points.AUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet;If you stay in your home long enough, you usually build enough equity that you can sell it for a profit. When you have to sell the property before then or during a downturn in the market, you may need to find out how to short sale a house.Historical equity short-Interest data for all listed tickers starting 2018 ... AUPH (Aurinia Pharmaceuticals Inc) Start Date:2013-11-08. AUR (Aurora Innovation ...

Aurinia Pharmaceuticals (AUPH) Short Interest Ratio & Short Volume $8.85 -0.39 (-4.22%) (As of 03:22 PM ET) Compare Today's Range $8.77 $10.05 50-Day Range $7.13 $9.24 52-Week Range $4.07 $12.43 Volume 6.25 million shs Average Volume 2.60 million shs Market Capitalization $1.27 billion P/E Ratio N/A Dividend Yield N/A Price Target $14.00

AUPH | Aurinia Pharmaceuticals by Finance Ai provides AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report with insider trading history and institutional ownership breakdown.

2021-12-27 Short sale volume (not short interest) for $JMIA is 33%. http://shortvolumes.com/?t=JMIA $ERIC 56% $SOS 58% $AUPH 42% $QLGN 52%. 28 Dec 2021WebAurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin ...AUPH has multiple downside risks that investors need to consider when managing their position. First, Aurinia is still recording losses and reported a net loss of $82.1M for the first three ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling ...Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month. Percent of FloatThe Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...Finding the right furnished short term rental can be a daunting task. With so many options available, it can be difficult to know which one is best for you. Here are some tips to help you make the right choice when selecting a furnished sho...Aurinia Pharmaceuticals (AUPH) traded ~5% higher pre-market Thursday after the co. raised its outlook and posted better-than-expected Q2 2023 financials. Read more here.Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ...

Short Squeeze - Canada; Short Squeeze - Hong Kong; Highest Cost to Borrow; Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand. Germany Switzerland Spain Poland Netherlands Greece France Ireland Italy Belgium …WebNov 24, 2023 · Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value. AUPH 4.86%. Apple Inc. $191.24. AAPL 0.68%. Sarepta Therapeutics Inc. ... Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance ...Instagram:https://instagram. how much is a 1964 50 cent piece worthbest silver stockbuyalerts.com costlaurence stein goldman Short Interest: 17.28M (10/31/23)Short Interest Change-0.88%: Percent of Float: 13.23% nysearca vtvapps to buy and sell stocks Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ...Aurinia Pharma press release (NASDAQ:AUPH): Q3 GAAP EPS of -$0.09 beats by $0.08.; Revenue of $54.52M (-2.3% Y/Y) beats by $16.02M. Achieved European pricing and reimbursement milestone triggering ... is option trading profitable Aurinia's Q4, 2022 earnings call, (the "Call"), delivered on 02/28/2023, provides a report on how Aurinia is doing a full two years on. During the Call CEO Greenleaf advised that Aurinia was ...Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Jun 30, 2023 · Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...